|
Cryoport Inc 's Long Term Debt to Equity
CYRX's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth
Due to net new long-term borrowings of 0.43%, Long Term Debt to Equity fell to 0.78, above the Cryoport Inc 's average Long Term Debt to Equity.
Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 37 other companies have achieved lower Long Term Debt to Equity than Cryoport Inc in the IV Quarter 2023. While Long Term Debt to Equity total ranking has improved so far in the forth quarter 2023 to 1163, from total ranking in the third quarter 2023 at 1708 .
Explain Long Term Debt to Equity Ratio?
How much Long Term Debt CYRX´s has?
What is the structure of CYRX´s Equity?
Select the Comparisons :
|
|
Select the Ratio:
|
Long Term Debt to Equity ▼
|
Long Term Debt to Equity ▼
|
CYRX Long Term Debt to Equity |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity Change |
-12.02 % |
-3.27 % |
-4.25 % |
-8.03 % |
-13.4 % |
Y / Y Long Term Debt Change |
-6.68 % |
-6.93 % |
0.62 % |
0.46 % |
0.45 % |
Long Term Debt to Equity MRQ |
0.78 |
0.7 |
0.75 |
0.73 |
0.73 |
CYRX's Total
Ranking |
# 1163 |
# 1708 |
# 1829 |
# 1876 |
# 2025 |
Seq. Equity Change |
-9.02 % |
-1.24 % |
-2.9 % |
0.84 % |
0.02 % |
Seq. Long Term Debt Change |
0.43 % |
-7.37 % |
0.15 % |
0.16 % |
0.16 % |
Long Term Debt to Equity forth quarter 2023 Company Ranking |
Within: |
No. |
Major Pharmaceutical Preparations Industry |
# 38 |
Healthcare Sector |
# 121 |
Overall Market |
# 1162 |
Long Term Debt to Equity Statistics |
High |
Average |
Low |
0.93 |
0.54 |
0.13 |
(Sep 30 2020) |
|
(Sep 30 2019) |
Cumulative Cryoport Inc 's Long Term Debt to Equity
CYRX's Long Term Debt to Equity for the trailling 12 Months
CYRX Long Term Debt to Equity |
(Dec 31 2023) IV. Quarter |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
Y / Y Equity TTM Growth |
-12.02 % |
-3.27 % |
-4.25 % |
-8.03 % |
-13.4 % |
Y / Y Long Term Debt TTM Growth |
-6.68 % |
-6.93 % |
0.62 % |
0.46 % |
0.45 % |
Long Term Debt to Equity TTM |
0.74 |
0.73 |
0.74 |
0.73 |
0.71 |
Total
Ranking TTM |
# 1132
| # 78
| # 112
| # 1764
| # 90
|
Seq. Equity TTM Growth |
-9.02 % |
-1.24 % |
-2.9 % |
0.84 % |
0.02 % |
Seq. Long Term Debt TTM Growth |
0.43 % |
-7.37 % |
0.15 % |
0.16 % |
0.16 % |
On the trailing twelve months basis Due to the net new long-term borrowings of 0.43% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeLong Term Debt to Equity improved to 0.74, a new company high. Long Term Debt to Equity is the average cumulative value over the last four quarters.
Among companies in the Major Pharmaceutical Preparations industry 43, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Cryoport Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 78 to 1132.
Explain Long Term Debt to Equity Ratio?
How much Long Term Debt CYRX´s has?
What is the structure of CYRX´s Equity?
TTM Long Term Debt to Equity Company Ranking |
Within: |
No. |
Within the Major Pharmaceutical Preparations Industry |
# 44 |
Healthcare Sector |
# 129 |
Within the Market |
# 1132 |
trailing twelve months Long Term Debt to Equity Statistics |
High |
Average |
Low |
0.74 |
0.4 |
0.06 | (Dec 31 2023) |
|
(Mar 31 2020) |
Companies with similar Long Term Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry | Long Term Debt to Equity | Dec 31 2023 MRQ Long Term Debt | Dec 31 2023 MRQ Equity | Blueprint Medicines Corporation | 1.90 | $ 247.733 Millions | $ 130.609 Millions | Travere Therapeutics Inc | 1.88 | $ 377.263 Millions | $ 200.810 Millions | Eli Lilly And Company | 1.69 | $ 18,320.800 Millions | $ 10,863.700 Millions | Phibro Animal Health Corporation | 1.66 | $ 448.853 Millions | $ 270.803 Millions | Ionis Pharmaceuticals Inc | 1.56 | $ 604.121 Millions | $ 386.686 Millions | G1 Therapeutics Inc | 1.46 | $ 51.557 Millions | $ 35.386 Millions | Alimera Sciences Inc | 1.40 | $ 64.489 Millions | $ 46.170 Millions | Jazz Pharmaceuticals Plc | 1.37 | $ 5,107.988 Millions | $ 3,736.997 Millions | Catalent Inc | 1.34 | $ 4,959.000 Millions | $ 3,687.000 Millions | Xoma Corporation | 1.34 | $ 118.518 Millions | $ 88.721 Millions | Zoetis Inc | 1.32 | $ 6,564.000 Millions | $ 4,991.000 Millions | Summit Therapeutics Inc | 1.29 | $ 100.000 Millions | $ 77.692 Millions | Bristol myers Squibb Company | 1.24 | $ 36,653.000 Millions | $ 29,485.000 Millions | Elanco Animal Health Inc | 0.92 | $ 5,736.000 Millions | $ 6,223.000 Millions | Merck and Co Inc | 0.89 | $ 33,683.000 Millions | $ 37,635.000 Millions | Ocular Therapeutix Inc | 0.82 | $ 74.925 Millions | $ 91.131 Millions | Viatris Inc | 0.79 | $ 16,188.100 Millions | $ 20,467.400 Millions | Cryoport inc | 0.78 | $ 379.888 Millions | $ 489.023 Millions | Perrigo Company Plc | 0.76 | $ 3,632.800 Millions | $ 4,767.900 Millions | Prestige Consumer Healthcare Inc | 0.75 | $ 1,199.340 Millions | $ 1,600.577 Millions | Verastem inc | 0.70 | $ 40.086 Millions | $ 57.374 Millions | Pfizer Inc | 0.69 | $ 61,538.000 Millions | $ 89,288.000 Millions | Emergent Biosolutions Inc | 0.69 | $ 446.500 Millions | $ 649.300 Millions | Ani Pharmaceuticals Inc | 0.66 | $ 284.819 Millions | $ 432.749 Millions | Mersana Therapeutics Inc | 0.63 | $ 23.148 Millions | $ 36.904 Millions | Royalty Pharma Plc | 0.61 | $ 6,135.285 Millions | $ 10,084.289 Millions | Aytu Biopharma Inc | 0.46 | $ 14.978 Millions | $ 32.853 Millions | Cumberland Pharmaceuticals Inc | 0.44 | $ 12.784 Millions | $ 29.260 Millions | Soligenix inc | 0.40 | $ 1.011 Millions | $ 2.522 Millions | Harmony Biosciences Holdings inc | 0.38 | $ 178.566 Millions | $ 466.992 Millions |
|